Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

The stock's fall snapped a four-day winning streak.

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas worldwide.

Shanghai-based brain-computer interface (BCI) company StairMed, which claims to outperform Elon Musk’s Neuralink in certain ...

Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...